NIAMS Clinical Trial Implementation Cooperative Agreement
National Institutes of Health (NIH)
Up to $250,000 direct costs for the UG3 phase
Project period limited to six years: up to one year for UG3 and up to five years for UH3
Support implementation of investigator-initiated, interventional clinical trials
Focus on high clinical impact within the research mission of NIAMS
Investigators conducting clinical trials
Patients with arthritis, musculoskeletal, and skin diseases
Reissue of PAR-24-208
Updated to align with agency priorities
Federal funding from NIH
Cooperative agreement mechanism
Addresses critical health issues related to arthritis and musculoskeletal diseases
Recurring funding opportunity
Higher Education Institutions
Public/State Controlled Institutions of Higher Education
Private Institutions of Higher Education
Nonprofits Other Than Institutions of Higher Education
For-Profit Organizations
Small Businesses
Local Governments
State Governments
County Governments
City or Township Governments
Indian/Native American Tribal Governments (Federally Recognized)
Indian/Native American Tribal Governments (Other than Federally Recognized)
Federal Governments
U.S. Territory or Possession
Other (e.g., Independent School Districts, Public Housing Authorities)
Completion of required registrations (SAM, eRA Commons, Grants.gov)
U.S. organizations eligible; foreign organizations not eligible
Investigators must have the skills, knowledge, and resources necessary to carry out the proposed research
Encouragement to engage individuals with lived experience in the research process
Clinical trials related to arthritis, musculoskeletal, and skin diseases
Successful completion of clinical trials with high clinical impact
Continuation of funding is conditional upon satisfactory progress and availability of funds
Experience in conducting clinical trials
Plans for monitoring and evaluating critical processes impacting trial feasibility
Limited to $250,000 direct costs for the UG3 phase
Payment details not specified
Open Date: February 04, 2025
Application Due Dates: Various dates through 2027
Milestones must be achieved prior to transition to UH3 phase
Compliance with NIH Grants Policy Statement and federal regulations
Clinical Monitoring Plan required
Study Timeline required
Scientific and technical merit evaluated through NIH peer review